21 May 2018 12:08
4D pharma plc
(the "Company" or "4D")
Result of AGM
At the annual general meeting of 4D pharma plc (AIM: DDDD), a pharmaceutical company leading the development of live biotherapeutics, held earlier today, all resolutions put to shareholders were duly passed.
The full text of each resolution was included in the notice of the meeting, which was posted to shareholders on 25 April 2018, and is available on the Company's website www.4dpharmaplc.com.
For further information please contact:
4D | + 44 (0)113 895 0130 |
Duncan Peyton, Chief Executive Officer
| |
Zeus Capital Limited - Nomad and Joint Broker | |
Dan Bate / Jordan Warburton | +44 (0) 161 831 1512 |
Hugh Kingsmill Moore
| +44 (0) 203 829 5000 |
Bryan Garnier & Co. Limited - Joint Broker | +44 (0)20 7332 2500 |
Dominic Wilson Phil Walker |
About 4D
Founded in February 2014, 4D is a world leader in the development of live biotherapeutics, a novel and emerging class of drugs, defined by the FDA as biological products that contain a live organism, such as a bacteria, that is applicable to the prevention, treatment or cure of a disease. 4D has developed a proprietary platform that rationally identifies novel bacteria that have a precise and evolved therapeutic effect. All of 4D's live biotherapeutic products are orally delivered single strains of bacteria that are naturally found in the healthy human gut. 4D has completed a phase I study in Irritable Bowel Syndrome and has completed dosing in a phase I study in Paediatric Crohn's Disease. It currently has a pipeline of 13 pre-clinical programmes, covering disease areas such as cancer, poorly controlled asthma, autoimmune and CNS disease, and plans to commence four additional clinical studies in 2018.